Pfizer’s Monthly GLP-1 Injection: One Shot Instead of Four

What if you only had to think about your GLP-1 injection once a month instead of every week? That’s the promise behind Pfizer’s PF’3944 (formerly MET-097i), an ultra-long-acting GLP-1 receptor agonist that the company acquired through its $10 billion purchase of biotech Metsera in late 2025. On February 3, 2026, Pfizer revealed Phase 2b results showing competitive weight loss with once-monthly dosing—a potential game-changer for patients who find weekly injections inconvenient or difficult to maintain.

The VESPER-3 Phase 2b Results

The VESPER-3 trial enrolled approximately 250 adults with obesity or overweight without type 2 diabetes. All participants receiving PF’3944 started with 12 weeks of weekly injections to establish tolerability, then switched to once-monthly dosing at a fourfold higher dose. Four different monthly dose levels were tested against placebo.

The fact that no plateau was observed at week 28 is particularly significant. The study continues through 64 weeks, and continued weight loss trajectory suggests the final numbers could be substantially higher. Pfizer’s Chief Scientific Officer Chris Boshoff stated that modeling predicts a higher monthly dose (9.6 mg) planned for Phase 3 could reach 16% weight loss at the same timepoint.

Why Monthly Dosing Matters

The convenience argument is straightforward: 12 injections per year instead of 52. But the practical implications go beyond simple math. Weekly injection schedules create friction in daily life—patients need to remember a specific day, maintain cold-chain storage, and plan around travel. Pfizer’s chief internal medicine officer Jim List noted that “weekly doesn’t work for everybody,” pointing out that patients who travel frequently struggle to keep their injections refrigerated.

Monthly dosing could also improve long-term adherence. Real-world data consistently shows that a significant percentage of patients discontinue GLP-1 therapy within the first year, and dosing frequency is one of the contributing factors. A once-monthly injection could help patients stay on therapy longer, which directly correlates with better outcomes.

There’s also a cost-of-care angle. Fewer injections mean fewer pharmacy visits, fewer shipping events (reducing cold-chain logistics costs), and potentially lower per-administration costs even if the drug price per dose is similar.

How It Compares to Weekly Injections

Cross-trial comparisons have significant limitations, but the numbers provide useful context. Eli Lilly’s Zepbound showed approximately 13% placebo-adjusted weight loss at 28 weeks in its pivotal trials. PF’3944’s 12.3% at the same timepoint is in the same ballpark, though Leerink Partners analyst David Risinger noted the data looks “slightly inferior” to Zepbound’s results.

However, several important caveats apply. The Phase 2b study tested lower doses than what Pfizer plans to use in Phase 3. The higher 9.6 mg monthly dose (equivalent to 2.4 mg weekly) hasn’t been fully characterized yet. And the study was at its midpoint—full 64-week results could close any gap. BMO Capital Markets analysts gave a “cautious welcome” to the data, noting the results look competitive “especially in the context of ongoing studies in combination with the company’s amylin asset.”

Pfizer’s Broader Obesity Strategy

PF’3944 isn’t Pfizer’s only obesity play. The company is developing it as both a weekly and once-monthly injection, as well as in combination with other treatments that target different gut hormones. Pfizer’s obesity pipeline also includes drugs targeting amylin and GIP receptors, and the company recently licensed rights to an oral GLP-1 candidate from YaoPharma. Plans span more than 20 trials in 2026, testing these drugs as standalone treatments and in combinations.

This is also a strategic imperative for Pfizer. The company faces a significant patent cliff in 2026–2027, with several major products losing exclusivity. Obesity is one of the key growth areas Pfizer is targeting to offset those losses, and they’re racing to launch PF’3944 as early as 2028.

What About Danuglipron? (It’s Done)

You may have heard about Pfizer’s oral GLP-1 drug, danuglipron. That program was discontinued in April 2025 after a participant in a dose-optimization study experienced potential drug-induced liver injury. While the liver enzyme elevations across the broader program were in line with other GLP-1 drugs, Pfizer decided the overall risk-benefit profile wasn’t competitive enough to justify Phase 3 investment. The monthly injectable PF’3944 is now the centerpiece of Pfizer’s obesity strategy.

Timeline: When Could This Be Available?

Pfizer is moving aggressively. The Phase 3 VESPER-4 trial (weekly dosing in obesity) has already been initiated, and the company plans to launch all 10 Phase 3 trials throughout 2026. Detailed VESPER-3 results will be presented at the American Diabetes Association Scientific Sessions in June 2026. If Phase 3 trials succeed, an NDA filing could come in 2027, with potential approval and launch in 2028.

For patients currently on weekly GLP-1 injections who find the dosing schedule burdensome, a monthly option represents a meaningful quality-of-life improvement. The efficacy data from VESPER-3 suggests that this convenience doesn’t come with a major efficacy tradeoff, and the Phase 3 program testing higher doses could bring results closer to—or even matching—current weekly options.